Wall Street analysts expect Juno Therapeutics, Inc. (NASDAQ:JUNO) to report $19.16 million in sales for the current quarter, Zacks reports. Five analysts have issued estimates for Juno Therapeutics’ earnings, with the lowest sales estimate coming in at $17.00 million and the highest estimate coming in at $21.30 million. Juno Therapeutics posted sales of $20.83 million in the same quarter last year, which would indicate a negative year over year growth rate of 8%. The business is scheduled to report its next quarterly earnings report on Wednesday, November 8th.
According to Zacks, analysts expect that Juno Therapeutics will report full year sales of $19.16 million for the current fiscal year, with estimates ranging from $66.00 million to $83.10 million. For the next financial year, analysts anticipate that the business will report sales of $84.77 million per share, with estimates ranging from $50.00 million to $161.85 million. Zacks Investment Research’s sales averages are an average based on a survey of research firms that cover Juno Therapeutics.
Juno Therapeutics (NASDAQ:JUNO) last issued its earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.96) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.72) by $0.24. The firm had revenue of $21.30 million during the quarter, compared to analyst estimates of $15.59 million. Juno Therapeutics had a negative net margin of 354.36% and a negative return on equity of 27.10%. The business’s quarterly revenue was down 22.8% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.64) earnings per share.
Several equities research analysts have recently commented on the stock. Vetr upgraded shares of Juno Therapeutics from a “strong sell” rating to a “sell” rating and set a $25.50 price target for the company in a report on Monday, August 14th. Zacks Investment Research lowered shares of Juno Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, August 10th. Morgan Stanley boosted their price target on shares of Juno Therapeutics from $26.00 to $27.00 and gave the company an “equal weight” rating in a report on Monday, August 7th. Wedbush restated a “neutral” rating and issued a $24.00 price target on shares of Juno Therapeutics in a report on Tuesday, June 6th. Finally, BidaskClub lowered shares of Juno Therapeutics from a “buy” rating to a “hold” rating in a report on Saturday, June 10th. Three equities research analysts have rated the stock with a sell rating, six have given a hold rating and six have assigned a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average price target of $29.27.
Shares of Juno Therapeutics (JUNO) traded up 1.35% during mid-day trading on Friday, hitting $30.73. The stock had a trading volume of 2,162,591 shares. The firm’s market capitalization is $3.22 billion. The stock’s 50-day moving average is $28.62 and its 200 day moving average is $25.14. Juno Therapeutics has a 1-year low of $17.52 and a 1-year high of $33.74.
In other Juno Therapeutics news, Director Richard Klausner sold 12,000 shares of the business’s stock in a transaction that occurred on Monday, August 7th. The shares were sold at an average price of $30.34, for a total transaction of $364,080.00. Following the sale, the director now owns 788,985 shares of the company’s stock, valued at approximately $23,937,804.90. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CFO Steve Harr sold 8,750 shares of the business’s stock in a transaction that occurred on Tuesday, June 27th. The stock was sold at an average price of $30.00, for a total transaction of $262,500.00. Following the sale, the chief financial officer now directly owns 736,189 shares in the company, valued at approximately $22,085,670. The disclosure for this sale can be found here. In the last three months, insiders have sold 8,053,500 shares of company stock worth $217,594,440. 15.26% of the stock is owned by insiders.
A number of hedge funds have recently added to or reduced their stakes in JUNO. M&T Bank Corp bought a new stake in Juno Therapeutics during the first quarter valued at $381,000. Nisa Investment Advisors LLC bought a new stake in Juno Therapeutics during the first quarter valued at $200,000. Laurion Capital Management LP bought a new stake in Juno Therapeutics during the first quarter valued at $390,000. Marshall Wace LLP bought a new stake in Juno Therapeutics during the second quarter valued at $1,071,000. Finally, Geode Capital Management LLC increased its stake in Juno Therapeutics by 8.9% in the first quarter. Geode Capital Management LLC now owns 595,136 shares of the biopharmaceutical company’s stock valued at $13,206,000 after buying an additional 48,516 shares in the last quarter. 65.03% of the stock is currently owned by institutional investors.
About Juno Therapeutics
Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.
Get a free copy of the Zacks research report on Juno Therapeutics (JUNO)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Juno Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juno Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
